Clinical trials: High Altitude Pulmonary Hypertension
High Altitude Pulmonary Hypertension
Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live >2500m on 6-minute walk distance (6MWD) assessed at 3200m.
- Trial name
- NCT06489743
- Testing
- 6-minute walk test (6MWT)
- Where
- Kyrgyzstan
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Pulmonary Hypertension
Acute Exposure of High Altitude on Cognitive Function
Randomized crossover Trial in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary Hypertension (CTEPH) to assess the acute response to High Altitude (2500m above sea level) on cognitive…
- Trial name
- NCT03637192
- Testing
- Low altitude: 470m above sea level, Säntis; 2500m above sea Level
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Healthy, Healthy Adult
Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Healthy Individuals
To study the effect of a re-ascent to high altitude (Quito Ecuador: 2850m) after a one-week stay at sea level (after prior descent from 2850m) on lung function and pulmonary resistance/reactance in healthy individuals, who live…
- Conditions
- Healthy, Healthy Adult, High Altitude Effects, High Altitude
- Trial name
- NCT07804537
- Testing
- Re-ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
High Altitude, Healthy
Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Healthy Individuals
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy…
- Conditions
- High Altitude, Healthy, Healthy Adult, High Altitude Effects
- Trial name
- NCT07804589
- Testing
- Re-Ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension, Mountain Sickness
Study of the Effects of Iron Levels on the Lungs at High Altitude
The study hypothesis is that body iron levels are important in determining the increase in lung blood pressure that occurs in response to low oxygen levels.
- Trial name
- NCT00952302
- Testing
- Iron sucrose, Normal saline, Venesection
- Where
- Peru
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Hypertension, Pulmonary
Study of the Effects of Iron on Lung Blood Pressure at High Altitude
Body iron levels may be important in determining how the blood pressure in the lungs changes in response to low oxygen levels. At high altitude, where oxygen levels are low, some patients develop elevated lung blood pressure.
- Trial name
- NCT00960921
- Testing
- Iron sucrose, Normal saline
- Where
- Kyrgyzstan
- Sponsor
- University of Oxford
Healthy, Healthy Adult
Sleep-Assessment in Patients Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on sleeping parameters by polygraphy in healthy individuals, who live permanently >2600m.
- Conditions
- Healthy, Healthy Adult, High Altitude Effects, High Altitude
- Trial name
- NCT07801950
- Testing
- Descent from 2850m to sea level and re-ascent back to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension
Acute Exposure to High Altitude on Symptoms
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) in altitude related symptoms
- Trial name
- NCT03593005
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension, Sleep Apnea
HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study.
- Trial name
- NCT06489730
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension, Sleep
Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension
The impact of hypoxia at 2500m of high altitude on sleep in patients with precapillary pulmonary hypertension
- Trial name
- NCT05089487
- Testing
- Nocturnal rest (sleep study)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
Right Ventricular Function During Exercise in Highlanders/Lowlanders
The purpose of the current study is to evaluate the right ventricular function during graded cycling on an ergometer by transthoracic echocardiography in Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by…
- Trial name
- NCT03165032
- Where
- Kyrgyzstan
- Volunteers
- 173 people
- Sponsor
- University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT05996302
- Testing
- Relocation to sea level
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension, Sleep Apnea
Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study.
- Trial name
- NCT03165019
- Where
- Kyrgyzstan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension, Oxygen Therapy
Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m
To study whether oxygen therapy titrated to maintain oxygenation (SpO2) > 90% at 2500m would resolve altitude-related adverse health effects, symptoms and impaired exercise during 30h exposure to high altitude.
- Trial name
- NCT05112172
- Testing
- Oxygen Therapy
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
Altitude Related Adverse Health Effects (ARAHE) in Patients With Precapillary Pulmonary Hypertension During 30h Exposure to 2500m
The interest of journeys to high altitude regions for recreational or professional purposes is increasing, also among potentially vulnerable groups including patients with chronic cardiopulmonary diseases such as pulmonary…
- Trial name
- NCT05107700
- Testing
- Stay at altitude 2500 m above sea level (high altitude), Stay at altitude 470 m above sea level (low altitude)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension
This is a Phase I, three period, two sequence, open-label, randomized, crossover study, with the primary objective of testing the safety and tolerability of combined oral doses of theophylline and bambuterol in healthy human…
- Trial name
- NCT01566565
- Testing
- Theophylline and Bambuterol
- Where
- Norway
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Norwegian Armed Forces Medical Service
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in patients with…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, High Altitude, Echocardiography
- Trial name
- NCT07804693
- Testing
- Re-Ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
High Altitude Polycythemia
Treatment of High Altitude Polycythemia by Acetazolamide
The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. There is no pharmacological treatment available.
- Trial name
- NCT00424970
- Testing
- acetazolamide
- Where
- Peru
- Volunteers
- 55 people
- Sponsor
- Association pour la Recherche en Physiologie de l'Environnement
High Altitude, Healthy Adult
Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.
- Conditions
- High Altitude, Healthy Adult, Echocardiography, Pulmonary Resistance
- Trial name
- NCT07804485
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in patients with pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Six-minute Walk Test, NYHA
- Trial name
- NCT07797166
- Testing
- Re-Ascent sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini